{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:39:40Z","timestamp":1792633180222,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Randomized trials demonstrated that in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) direct oral anticoagulants (DOAC) and a P2Y12 inhibitor reduce bleeding compared with vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) with no increase in ischemic risk; however, important gaps in knowledge remain, limiting certainty and generalizability of these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this patient-level meta-analysis of randomized trials evaluating antithrombotic strategies in patients with AF undergoing PCI, Cox proportional hazard models, stratified by trial, were used to estimate hazard ratios and 95% confidence intervals (HR, 95% CI). The primary efficacy and safety outcomes were the composite of cardiovascular death, myocardial infarction, or stroke, and TIMI major bleeding, respectively. The study was registered in PROSPERO (CRD420251130025).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six trials (10 634 patients) comparing DOAC plus P2Y12 inhibitor (4083), VKA plus single antiplatelet therapy (SAPT, 1247), VKA plus DAPT (3715), and DOAC plus DAPT (1589) were included. The transition from DAPT to SAPT was recommended at 1 (1\u20133) and 3 (1\u20137) days in the DOAC plus P2Y12 inhibitor and VKA plus SAPT groups, respectively. At 1 year, the risk of the primary efficacy outcome did not differ across the antithrombotic strategies (reference group: VKA plus DAPT; DOAC plus P2Y12 inhibitor: HR 1.16, 95% CI 0.97\u20131.41; VKA plus SAPT: 1.14, 0.85\u20131.54, DOAC plus DAPT: 0.99, 0.75\u20131.30), without any statistically significant interaction between treatment effects and all prespecified subgroups, including age, sex, bleeding risk, and thrombotic risk. However, 14-day landmark analysis showed an increased risk of myocardial infarction and definite\/probable stent thrombosis in patients receiving DOAC plus P2Y12 inhibitor or VKA plus SAPT in the early phase after PCI. DOAC plus P2Y12 inhibitor reduced the risk of the primary safety outcome compared with VKA plus DAPT (0.48, 0.38\u20130.65) and VKA plus SAPT (0.62, 0.40\u20130.97); only a borderline reduction was observed compared to DOAC plus DAPT (0.66, 0.44\u20131.01). DOAC plus P2Y12 inhibitor reduced intracranial haemorrhage compared with VKA plus DAPT (0.21, 0.07\u20130.64).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with AF undergoing PCI, the risk of cardiovascular death, myocardial infarction, or stroke did not significantly differ according to whether patients received a DOAC or VKA, whereas a modest increase in risk with single compared with dual antiplatelet therapy cannot be excluded, given the higher risk of early coronary events. DOACs compared with VKAs reduced the risk of bleeding across all severity grades, including intracranial haemorrhage, whereas omission of a second antiplatelet agent reduced the risk of TIMI major or minor bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag740","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T13:16:32Z","timestamp":1788095792000},"source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-2658","authenticated-orcid":false,"given":"Mauro","family":"Chiarito","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan 20072 ,","place":["Italy"]},{"name":"IRCCS Humanitas Research Hospital Cardio Center, , Rozzano, Milan 20089 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Gibson","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School , Boston ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Cannon","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Heart and Vascular Center and Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Division of Cardiology, , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-9409","authenticated-orcid":false,"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-7563","authenticated-orcid":false,"given":"Angelo","family":"Oliva","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan 20072 ,","place":["Italy"]},{"name":"Mount Sinai Fuster Heart Hospital, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Smith","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Feng","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Lampert","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-7209","authenticated-orcid":false,"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital , Paderborn ,","place":["Germany"]},{"name":"Medical Faculty, Otto-von-Guericke University Magdeburg , Magdeburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4341-891X","authenticated-orcid":false,"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[{"name":"Klinik F\u00fcr Herz- und Kreislauferkrankungen, TUM Klinikum Deutsches Herzzentrum, Technische Universit\u00e4t M\u00fcnchen , Munich 80636 ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-7606","authenticated-orcid":false,"given":"Ruth","family":"Owen","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine Department of Medical Statistics, , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien M","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Antonius Hospital , Nieuwegein ,","place":["The Netherlands"]},{"name":"Cardiovascular Research Institute Maastricht Department of Cardiology, , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-6951","authenticated-orcid":false,"given":"Freek W A","family":"Verheugt","sequence":"additional","affiliation":[{"name":"Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Critical Care Medicine, Jessa Ziekenhuis , Stadsomvaart 11, Hasselt 3500 ,","place":["Belgium"]},{"name":"Faculty of Medicine and Life Sciences, University of Hasselt , Martelarenlaan 42, Hasselt 3500 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-7110","authenticated-orcid":false,"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Cardiocentro Institute, Ente Ospedaliero Cantonale, Universit\u00e0 Della Svizzera Italiana (USI) , Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Alexander","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Division of Cardiology, , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-4007","authenticated-orcid":false,"given":"Stuart","family":"Pocock","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine Department of Medical Statistics, , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"2026102120520115800_ehag740-B1","doi-asserted-by":"publisher","first-page":"E347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"2026102120520115800_ehag740-B2","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.4244\/EIJV8I9A163","article-title":"Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents","volume":"8","author":"Pilgrim","year":"2013","journal-title":"EuroIntervention"},{"key":"2026102120520115800_ehag740-B3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"2026102120520115800_ehag740-B4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102120520115800_ehag740-B5","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026102120520115800_ehag740-B6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102120520115800_ehag740-B7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2026102120520115800_ehag740-B8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"2026102120520115800_ehag740-B9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026102120520115800_ehag740-B10","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"2026102120520115800_ehag740-B11","doi-asserted-by":"publisher","first-page":"f50","DOI":"10.1093\/ehjcvp\/pvaa116","article-title":"Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"7","author":"Gargiulo","year":"2021","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"key":"2026102120520115800_ehag740-B12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/europace\/euz259","article-title":"Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trails","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"2026102120520115800_ehag740-B13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"2026102120520115800_ehag740-B14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/14651858.CD201601","article-title":"A revised tool for assessing risk of bias in randomized trials","volume":"29","author":"Higgins","year":"10","journal-title":"Cochrane Database Syst Rev 2016"},{"key":"2026102120520115800_ehag740-B15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"key":"2026102120520115800_ehag740-B16","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2026102120520115800_ehag740-B17","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2026102120520115800_ehag740-B18","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026102120520115800_ehag740-B19","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102120520115800_ehag740-B20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2026102120520115800_ehag740-B21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs","volume":"386","author":"Verheugt","year":"2015","journal-title":"Lancet"},{"key":"2026102120520115800_ehag740-B22","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102120520115800_ehag740-B23","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2026102120520115800_ehag740-B24","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.jacc.2017.08.018","article-title":"Characterization of the average daily ischemic and bleeding risk after primary PCI for STEMI","volume":"70","author":"Giustino","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026102120520115800_ehag740-B25","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Mechanisms of disease: platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"2026102120520115800_ehag740-B26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurheartj\/ehw525","article-title":"Trade-off of myocardial infarction vs. Bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2026102120520115800_ehag740-B27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102120520115800_ehag740-B28","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"2026102120520115800_ehag740-B29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S0140-6736(26)00665-3","article-title":"1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial","volume":"408","author":"Sotomi","year":"2026","journal-title":"Lancet"},{"key":"2026102120520115800_ehag740-B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ahj.2025.02.011","article-title":"Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: rationale and design of the phase 3 (Librexia ACS)","volume":"285","author":"Gibson","year":"2025","journal-title":"Am Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag740\/70870543\/ehag740.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag740\/70870543\/ehag740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag740\/70870543\/ehag740.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:52:07Z","timestamp":1792630327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag740\/8776127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag740","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]},"article-number":"ehag740"}}